Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
"Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS.
| Descriptor ID |
D000069480
|
| MeSH Number(s) |
D02.705.429.906.750 D03.383.742.680.245.500.600.750 D03.633.100.759.138.881.750 D13.570.230.329.525.500 D13.570.685.245.500.600.500 D26.310.423
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination".
- Chemicals and Drugs [D]
- Organic Chemicals [D02]
- Organophosphorus Compounds [D02.705]
- Organophosphonates [D02.705.429]
- Tenofovir [D02.705.429.906]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D02.705.429.906.750]
- Heterocyclic Compounds [D03]
- Heterocyclic Compounds, 1-Ring [D03.383]
- Pyrimidines [D03.383.742]
- Pyrimidine Nucleosides [D03.383.742.680]
- Cytidine [D03.383.742.680.245]
- Deoxycytidine [D03.383.742.680.245.500]
- Emtricitabine [D03.383.742.680.245.500.600]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D03.383.742.680.245.500.600.750]
- Heterocyclic Compounds, Fused-Ring [D03.633]
- Heterocyclic Compounds, 2-Ring [D03.633.100]
- Purines [D03.633.100.759]
- Adenine [D03.633.100.759.138]
- Tenofovir [D03.633.100.759.138.881]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D03.633.100.759.138.881.750]
- Nucleic Acids, Nucleotides, and Nucleosides [D13]
- Nucleosides [D13.570]
- Deoxyribonucleosides [D13.570.230]
- Deoxycytidine [D13.570.230.329]
- Emtricitabine [D13.570.230.329.525]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D13.570.230.329.525.500]
- Pyrimidine Nucleosides [D13.570.685]
- Cytidine [D13.570.685.245]
- Deoxycytidine [D13.570.685.245.500]
- Emtricitabine [D13.570.685.245.500.600]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D13.570.685.245.500.600.500]
- Pharmaceutical Preparations [D26]
- Drug Combinations [D26.310]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D26.310.423]
Below are MeSH descriptors whose meaning is more specific than "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination".
This graph shows the total number of publications written about "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" by people in this website by year, and whether "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" by people in Profiles.
-
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018 11; 5(11):e629-e637.
-
Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention. Am J Epidemiol. 2015 Nov 15; 182(10):848-56.
-
Murnane, Coley, and Baeten respond to "every good randomization deserves observation". Am J Epidemiol. 2015 Nov 15; 182(10):861-2.
-
Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med. 2013 Jan; 44(1 Suppl 2):S125-8.